$3.31
+0.19
(+6.09%)▲
Live
3.93%
Downside
Day's Volatility :5.36%
Upside
1.49%
21.15%
Downside
52 Weeks Volatility :90.46%
Upside
87.9%
Period | Rapt Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -61.48% | 6.5% | 0.0% |
6 Months | -87.66% | 7.1% | 0.0% |
1 Year | -87.01% | 9.8% | 0.0% |
3 Years | -90.14% | 14.2% | -20.2% |
Market Capitalization | 110.3M |
Book Value | $3.76 |
Earnings Per Share (EPS) | -3.08 |
Wall Street Target Price | 14.83 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -39.6% |
Return On Equity TTM | -67.21% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 1.5M |
EBITDA | -126.8M |
Diluted Eps TTM | -3.08 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.64 |
EPS Estimate Next Year | -2.04 |
EPS Estimate Current Quarter | -0.81 |
EPS Estimate Next Quarter | -0.83 |
What analysts predicted
Upside of 348.04%
Sell
Neutral
Buy
Rapt Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Rapt Therapeutics Inc | 2.3% | -87.66% | -87.01% | -90.14% | -76.0% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Rapt Therapeutics Inc | NA | NA | NA | -2.64 | -0.67 | -0.4 | NA | 3.76 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Rapt Therapeutics Inc | Buy | $110.3M | -76.0% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Rapt Therapeutics Inc
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 148.6%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 276.6%
FMR Inc
Column Group LLC
Vanguard Group Inc
BlackRock Inc
T. Rowe Price Associates, Inc.
Morgan Stanley - Brokerage Accounts
rapt therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. rapt has discovered and advanced two unique drug candidates, flx475 and rpt193, each targeting c-c motif chemokine receptor 4 (ccr4), for the treatment of cancer and inflammation, respectively. the company is also pursuing a range of targets that are in the discovery stage of development.
Organization | Rapt Therapeutics Inc |
Employees | 126 |
CEO | Dr. Brian Russell Wong M.D., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.31
+6.09%
Keyarch Acquisition Corp
$3.31
+6.09%
Connexa Sports Technologies Inc
$3.31
+6.09%
Us Value Etf
$3.31
+6.09%
First Wave Biopharma Inc
$3.31
+6.09%
Global X Msci Next Emerging
$3.31
+6.09%
Fat Projects Acquisition Corp
$3.31
+6.09%
Capital Link Global Fintech
$3.31
+6.09%
Applied Uv Inc
$3.31
+6.09%